SCHEMBL447309

SCHEMBL447309

CC1CCc2ccc(Br)cc2C1=O

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
PARP1 P09874 1/20 0.47
PARP10 Q53GL7 1/20 0.47
ACHE P22303 4/20 0.45
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
HTR2B P41595 1/20 0.41
PBRM1 Q86U86 1/20 0.41
TYMS P04818 2/20 0.40
SRD5A1 P18405 1/20 0.38
S100A4 P26447 1/20 0.38
METAP1 P53582 2/20 0.38
CYP19A1 P11511 1/20 0.37
TDP2 O95551 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10687118 0.86 PARP10 (0.47) TDP1L3MBTL1PARP1PARP10ACHE
SCHEMBL24483566 0.83 PBRM1 (0.53) L3MBTL1ACHEPBRM1CYP19A1
SCHEMBL29980313 0.82 ACHE (0.66) TDP1L3MBTL1PARP1PARP10ACHE
SCHEMBL6475805 0.82 ACHE (0.66) TDP1L3MBTL1PARP1PARP10ACHE
SCHEMBL6187453 0.81 PARP10 (0.49) TDP1L3MBTL1PARP1PARP10PBRM1
SCHEMBL8693800 0.81 ACHE (0.69) PARP1PARP10ACHETYMSSRD5A1
SCHEMBL29116309 0.79 PARP10 (0.47) TDP1L3MBTL1PARP1PARP10PBRM1
SCHEMBL30715513 0.79 PARP10 (0.47) TDP1L3MBTL1PARP1PARP10PBRM1
SCHEMBL29116217 0.79 PARP10 (0.47) TDP1L3MBTL1PARP1PARP10PBRM1
SCHEMBL30715512 0.79 PARP10 (0.47) TDP1L3MBTL1PARP1PARP10PBRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4622716-A1 SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS Treeline Biosciences, Inc. (US) 2025-10-01 EP disclosed
WO-2024112654-A1 SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS Treeline Biosciences, Inc. (US) 2024-05-30 WO disclosed
WO-2023132606-A1 NOVEL ISOINDOLINONE DERIVATIVE COMPOUNDS AS CASPASE INHIBITORS 주식회사 이노보테라퓨틱스 2023-07-13 WO disclosed
US-9624202-B2 Heterocyclic amides as kinase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-04-18 US disclosed
US-20120065195-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. 2012-03-15 US disclosed
WO-2011123674-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. (US) 2011-10-06 WO disclosed
US-20100197711-A1 BENZOTHIAZOLE COMPOUNDS THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2010-08-05 US disclosed
EP-2193127-A1 BENZOTHIAZOLE COMPOUNDS The Walter and Eliza Hall Institute of Medical Research (AU) 2010-06-09 EP disclosed
WO-2009039553-A1 BENZOTHIAZOLE COMPOUNDS THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) 2009-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197711-A1 BENZOTHIAZOLE COMPOUNDS BAD, BCL2, BAX TDP1 1145/4885L3MBTL1 78/4885PARP1 526/4885
US-20120065195-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES APP, BACE1, PSEN1 TDP1 200/4885L3MBTL1 4213/4885PARP1 1287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.